世界の治療用抗体市場（2023年版）：抗体タイプ別（モノクローナル、二重特異性、薬物複合体、その他）、供給源別（完全ヒト、ヒト化、その他）、用途別、地域別、国別の分析：市場インサイトと予測（2019-2029年）

Global Therapeutic Antibody Market (2023 Edition): Analysis By Antibody Type (Monoclonal, Bispecific, Drug Conjugates, Others), Source (Fully human, Humanized, Others), By Application, By Region, By Country: Market Insights and Forecast (2019-2029)

エグゼクティブ・サマリーこの調査レポートは世界の治療用抗体産業を製品タイプ別（モノクローナル抗体、二重特異性抗体、その他）、供給源別（完全ヒト化抗体、ヒト化抗体、その他）、用途別（腫瘍学、自己... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2024年2月1日	US$2,450 シングルユーザライセンスライセンス・価格情報注文方法はこちら	260	英語

サマリー

エグゼクティブ・サマリー

この調査レポートは世界の治療用抗体産業を製品タイプ別（モノクローナル抗体、二重特異性抗体、その他）、供給源別（完全ヒト化抗体、ヒト化抗体、その他）、用途別（腫瘍学、自己免疫疾患、感染症、その他）、地域別、国別に詳細に分析しています、抗体薬物複合体、その他）、供給源別（完全ヒト型、ヒト化、その他）、用途別（腫瘍、自己免疫、感染症、その他）、地域別、国別に、2019-2022年の過去期間、2023年の推定期間、2024-2029年の予測期間について分析しています。

この調査レポートは、地域（米州、欧州、APAC、中東アフリカ）と10カ国（米国、カナダ、英国、ドイツ、フランス、スペイン、中国、日本、韓国、インド）の詳細な分析をカバーしています。さらに、市場規模、年間成長＆潜在力分析、市場プレイヤーの競合調査、投資機会、需要予測などのデータも掲載しています。

この調査レポートは、成長指標、阻害要因、需給リスク、その他の重要な統計、市場の進化に関連する現在および将来の市場動向の完全な評価も行っています。

世界の治療用抗体市場は、2022年の2112億米ドルから2029年末までに4282億米ドルを創出すると予測される。世界の治療用抗体市場の好ましい成長要素は、慢性疾患の有病率の増加、バイオテクノロジーの進歩、個別化医療の可能性によって推進されています。2024-2029年の予測期間中、世界の治療用抗体はCAGR 11.2%で拡大すると予想される。バイオプロセスと製造技術の進歩は現在も続いている。これらの改善は、効率性の向上、コストの削減、より持続可能な治療用抗体の生産につながります。

世界保健機関（WHO）によると、非感染性疾患（NCDs）により毎年4,100万人が死亡しており、これは世界全体の死亡者数の74％に相当する。がん、自己免疫疾患、炎症性疾患を含む慢性疾患の罹患率の増加は、抗体治療薬市場の主要な促進要因である。抗体は、これらの疾病に関与する特定の分子を標的として設計することができ、標的を絞った効果的な治療を提供することができる。

COVID-19のパンデミックは、感染症管理における抗体治療の重要性を浮き彫りにした。抗体が開発され、COVID-19の緊急治療薬として認可されたことは、世界的な健康問題への対処における抗体の可能性を浮き彫りにしている。パンデミック時に効果的な治療法が緊急に必要とされたため、開発、臨床試験、薬事承認プロセスが迅速に行われた。このことは、新たな健康危機に対応する業界と規制当局の機敏さを実証している。

がんは世界的に主要な死因であり、2020年には約1,000万人、つまり死亡者の約6人に1人ががんで死亡することになる。精密医療の進歩とがんバイオマーカーの発見は、個別化抗体療法の開発に貢献している。特定の分子標的を特定することで、個々の患者や特定のがんサブタイプに合わせた抗体の設計が可能になる。

研究者たちは、標的抗原に対する特異性と親和性を向上させた抗体の開発を続けている。これにより、副作用の少ない、より効果的で正確な治療介入が可能になる。ナノ抗体、二重特異性抗体、多重特異性抗体などの新しい抗体フォーマットの開発により、治療能力と応用が拡大する。

世界の抗体治療薬市場におけるヒト化ソースの利用は、安全性と有効性の向上から標的ポートフォリオの拡大、高度な工学的アプローチの実現まで、さまざまな機会を提供する。これらの機会は、抗体ベースの治療法の継続的な成長と多様化に寄与しています。抗体工学の進歩により、治療特性を改善するための抗体構造の改変が可能になりました。この技術には、免疫原性を低減するためのヒト化、標的抗原への結合を強化するための親和性成熟化、エフェクター機能を最適化するためのアイソタイプスイッチングなどが含まれる。

レポートの範囲

- 本レポートでは、治療用抗体市場を金額（10億米ドル）別に分析しています。

- 2019-2022年の過去期間、2023年の推定期間、2024-2029年の予測期間における治療用抗体市場の分析を掲載しています。

- 治療用抗体市場を製品タイプ別（モノクローナル抗体、二重特異性抗体、抗体薬物複合体、その他）に分析しています。

- 治療用抗体市場を供給源別（完全ヒト、ヒト化、その他）に分析しています。

- 治療用抗体市場を用途別（腫瘍、自己免疫、感染症、その他）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、サービス別、運用形態別、エンドユーザー別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- レポートでは、競合の動向、戦略、M&A、新製品開発などを追跡しています。本レポートで分析している企業は、F.ホフマン・ラ・ロシュ社、ブリストル・マイヤーズスクイブ社、アッヴィ社、メルク社、ジョンソン・エンド・ジョンソン社、ノバルティス社、リジェネロン社、武田薬品工業社、アムジェン社、イーライリリー・アンド・カンパニー社などです。

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

3. Global Therapeutic Antibody Market: Historic and Forecast (2019-2029)

3.1 Impact Analysis of Macro Economic Factors on the Global Therapeutic Antibody Market

3.2 Pipeline Scenario

3.3 Epidemiology: Global Chronic Disease Prevalence

3.4 Epidemiology: Global Chronic Disease Incidence

3.5 Global Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

3.6 Degree of Impact of Covid-19 on Therapeutic Antibody Market

3.7 Global Therapeutic Antibody Market Segmentation: By Product Type

3.7.1 Global Therapeutic Antibody Market, By Product Type Overview

3.7.2 Global Therapeutic Antibody Market Size, By Monoclonal Antibody, By Value, 2019H-2029F (USD Billion & CAGR)

3.7.3 Global Therapeutic Antibody Market Size, By Bispecific Antibody, By Value, 2019H-2029F (USD Billion & CAGR)

3.7.4 Global Therapeutic Antibody Market Size, By Antibody-drug conjugates, By Value, 2019H-2029F (USD Billion & CAGR)

3.7.5 Global Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

3.8 Global Therapeutic Antibody Market Segmentation: By Source

3.8.1 Global Therapeutic Antibody Market, By Source Overview

3.8.2 Global Therapeutic Antibody Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)

3.8.3 Global Therapeutic Antibody Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)

3.8.4 Global Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

3.9 Global Therapeutic Antibody Market Segmentation: By Application

3.9.1 Global Therapeutic Antibody Market, By Application Overview

3.9.2 Global Therapeutic Antibody Market Size, By Oncology, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.3 Global Therapeutic Antibody Market Size, By Autoimmune, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.4 Global Therapeutic Antibody Market Size, By Infectious Disease, By Value, 2019H-2029F (USD Billion & CAGR)

3.9.5 Global Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

4. Global Therapeutic Antibody Market, Regional Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot

5. Americas Therapeutic Antibody Market: Historic and Forecast (2019-2029)

5.1 Americas Therapeutic Antibody Market: Snapshot

5.2 Americas Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

5.3 Americas Therapeutic Antibody Market: Key Factors

5.4 Americas Therapeutic Antibody Market: Segment Analysis

5.5 Americas Therapeutic Antibody Market Segmentation: By Product Type

5.5.1 Americas Therapeutic Antibody Market, By Product Type Overview

5.5.2 Americas Therapeutic Antibody Market Size, By Monoclonal Antibody, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.3 Americas Therapeutic Antibody Market Size, By Bispecific Antibody, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.4 Americas Therapeutic Antibody Market Size, By Antibody-drug conjugates, By Value, 2019H-2029F (USD Billion & CAGR)

5.5.5 Americas Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

5.6 Americas Therapeutic Antibody Market Segmentation: By Source

5.6.1 Americas Therapeutic Antibody Market, By Source Overview

5.6.2 Americas Therapeutic Antibody Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)

5.6.3 Americas Therapeutic Antibody Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)

5.6.4 Americas Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

5.7 Americas Therapeutic Antibody Market Segmentation: By Application

5.7.1 Americas Therapeutic Antibody Market, By Application Overview

5.2.2 Americas Therapeutic Antibody Market Size, By Oncology, By Value, 2019H-2029F (USD Billion & CAGR)

5.7.3 Americas Therapeutic Antibody Market Size, By Autoimmune, By Value, 2019H-2029F (USD Billion & CAGR)

5.7.4 Americas Therapeutic Antibody Market Size, By Infectious Disease, By Value, 2019H-2029F (USD Billion & CAGR)

5.7.5 Americas Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

5.8 Americas Therapeutic Antibody Market Segmentation: By Country

5.8.1 Americas Therapeutic Antibody Market, By Country Overview

5.8.2 United States Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

5.8.2.1 United States Therapeutic Antibody Market, By Product Type

5.8.2.2 United States Therapeutic Antibody Market, By Source

5.8.2.3 United States Therapeutic Antibody Market, By Application

5.8.3 Canada Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

5.8.3.1 Canada Therapeutic Antibody Market, By Product Type

5.8.3.2 Canada Therapeutic Antibody Market, By Source

5.8.3.3 Canada Therapeutic Antibody Market, By Application

5.10.4 Rest of Americas Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

5.10.4.1 Rest of Americas Therapeutic Antibody Market, By Product Type

5.10.4.2 Rest of Americas Therapeutic Antibody Market, By Source

5.10.4.3 Rest of Americas Therapeutic Antibody Market, By Application

6. Europe Therapeutic Antibody Market: Historic and Forecast (2019-2029)

6.1 Europe Therapeutic Antibody Market: Snapshot

6.2 Europe Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.3 Europe Therapeutic Antibody Market: Key Factors

6.4 Europe Therapeutic Antibody Market: Segment Analysis

6.5 Europe Therapeutic Antibody Market Segmentation: By Product Type

6.5.1 Europe Therapeutic Antibody Market, By Product Type Overview

6.5.2 Europe Therapeutic Antibody Market Size, By Monoclonal antibody, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.3 Europe Therapeutic Antibody Market Size, By Bispecific antibody, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.4 Europe Therapeutic Antibody Market Size, By Antibody drug conjugates, By Value, 2019H-2029F (USD Billion & CAGR)

6.7.5 Europe Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

6.6 Europe Therapeutic Antibody Market Segmentation: By Source

6.6.1 Europe Therapeutic Antibody Market, By Source Overview

6.6.2 Europe Therapeutic Antibody Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)

6.6.3 Europe Therapeutic Antibody Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)

6.6.4 Europe Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

6.7 Europe Therapeutic Antibody Market Segmentation: By Application

6.7.1 Europe Therapeutic Antibody Market, By Application Overview

6.5.2 Europe Therapeutic Antibody Market Size, By Oncology, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.3 Europe Therapeutic Antibody Market Size, By Autoimmune, By Value, 2019H-2029F (USD Billion & CAGR)

6.5.4 Europe Therapeutic Antibody Market Size, By Infectious Disease, By Value, 2019H-2029F (USD Billion & CAGR)

6.7.5 Europe Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

6.8 Europe Therapeutic Antibody Market Segmentation: By Country

6.8.1 Europe Therapeutic Antibody Market, By Country Overview

6.8.2 United Kingdom Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.8.2.1 United Kingdom Therapeutic Antibody Market, By Product Type

6.8.2.2 United Kingdom Therapeutic Antibody Market, By Source

6.8.2.3 United Kingdom Therapeutic Antibody Market, By Application

6.8.3 Germany Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.8.3.1 Germany Therapeutic Antibody Market, By Product Type

6.8.3.2 Germany Therapeutic Antibody Market, By Source

6.8.3.3 Germany Therapeutic Antibody Market, By Application

6.8.4 France Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.8.4.1 France Therapeutic Antibody Market, By Product Type

6.8.4.2 France Therapeutic Antibody Market, By Source

6.8.4.3 France Therapeutic Antibody Market, By Application

6.8.5 Spain Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.8.5.1 Spain Therapeutic Antibody Market, By Product Type

6.8.5.2 Spain Therapeutic Antibody Market, By Source

6.8.5.3 Spain Therapeutic Antibody Market, By Application

6.8.7 Rest of Europe Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

6.8.6.1 Rest of Europe Therapeutic Antibody Market, By Product Type

6.8.6.2 Rest of Europe Therapeutic Antibody Market, By Source

6.8.6.3 Rest of Europe Therapeutic Antibody Market, By Application

7. Asia Pacific Therapeutic Antibody Market: Historic and Forecast (2019-2029)

7.1 Asia Pacific Therapeutic Antibody Market: Snapshot

7.2 Asia Pacific Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.3 Asia Pacific Therapeutic Antibody Market: Key Factors

7.4 Asia Pacific Therapeutic Antibody Market: Segment Analysis

7.5 Asia Pacific Therapeutic Antibody Market Segmentation: By Product Type

7.5.1 Asia Pacific Therapeutic Antibody Market, By Product Type Overview

7.5.2 Asia Pacific Therapeutic Antibody Market Size, By Monoclonal antibody, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.3 Asia Pacific Therapeutic Antibody Market Size, By Bispecific antibody, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.4 Asia Pacific Therapeutic Antibody Market Size, By Antibody-drug conjugates, By Value, 2019H-2029F (USD Billion & CAGR)

7.7.5 Asia Pacific Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

7.6 Asia Pacific Therapeutic Antibody Market Segmentation: By Source

7.6.1 Asia Pacific Therapeutic Antibody Market, By Source Overview

7.6.2 Asia Pacific Therapeutic Antibody Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)

7.6.3 Asia Pacific Therapeutic Antibody Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)

7.6.4 Asia Pacific Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

7.7 Asia Pacific Therapeutic Antibody Market Segmentation: By Application

7.7.1 Asia Pacific Therapeutic Antibody Market, By ApplicationOverview

7.7.2 Asia Pacific Therapeutic Antibody Market Size, By Oncology, By Value, 2019H-2029F (USD Billion & CAGR)

7.7.3 Asia Pacific Therapeutic Antibody Market Size, By Autoimmune, By Value, 2019H-2029F (USD Billion & CAGR)

7.5.4 Asia Pacific Therapeutic Antibody Market Size, By Infectious Disease, By Value, 2019H-2029F (USD Billion & CAGR)

7.7.5 Asia Pacific Therapeutic Antibody Market Size, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

7.8 Asia Pacific Therapeutic Antibody Market Segmentation: By Country

7.8.1 Asia Pacific Therapeutic Antibody Market, By Country Overview

7.8.2 China Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.8.2.1 China Therapeutic Antibody Market, By Product Type

7.8.2.2 China Therapeutic Antibody Market, By Source

7.8.2.3 China Therapeutic Antibody Market, By Application

7.8.3 Japan Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.8.3.1 Japan Therapeutic Antibody Market, By Product Type

7.8.3.2 Japan Therapeutic Antibody Market, By Source

7.8.3.3 Japan Therapeutic Antibody Market, By Application

7.8.4 South Korea Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.8.4.1 South Korea Therapeutic Antibody Market, By Product Type

7.8.4.2 South Korea Therapeutic Antibody Market, By Source

7.8.4.3 South Korea Therapeutic Antibody Market, By Application

7.8.5 India Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.8.5.1 India Therapeutic Antibody Market, By Product Type

7.8.5.2 India Therapeutic Antibody Market, By Source

7.8.5.3 India Therapeutic Antibody Market, By Application

7.8.6 Rest of Asia Pacific Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

7.8.6.1 Rest of Asia Pacific Therapeutic Antibody Market, By Product Type

7.8.6.2 Rest of Asia Pacific Therapeutic Antibody Market, By Source

7.8.6.3 Rest of Asia Pacific Therapeutic Antibody Market, By Application

8. Middle East and Africa Therapeutic Antibody Market: Historic and Forecast (2019-2029)

8.1 Middle East and Africa Therapeutic Antibody Market: Snapshot

8.2 Middle East and Africa Therapeutic Antibody Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)

8.3 Middle East and Africa Therapeutic Antibody Market: Key Factors

8.4 Middle East and Africa Therapeutic Antibody Market: Segment Analysis

8.5 Middle East and Africa Therapeutic Antibody Market Segmentation: By Product Type

8.5.1 Middle East and Africa Therapeutic Antibody Market, By Product Type Overview

8.5.2 Middle East and Africa Therapeutic Antibody Market Size, By Monoclonal Antibody, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.3 Middle East and Africa Therapeutic Antibody Market, By Bispecific Antibody, By Value, 2019H-2029F (USD Billion & CAGR)

8.5.4 Middle East and Africa Therapeutic Antibody Market Size, By Antibody-drug conjugates, By Value, 2019H-2029F (USD Billion & CAGR)

8.7.5 Middle East and Africa Therapeutic Antibody Market, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

8.6 Middle East and Africa Therapeutic Antibody Market Segmentation: By Source

8.6.1 Middle East and Africa Therapeutic Antibody Market, By Source Overview

8.6.2 Middle East and Africa Therapeutic Antibody Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)

8.6.3 Middle East and Africa Therapeutic Antibody Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)

8.6.4 Middle East and Africa Therapeutic Antibody Market, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

8.7 Middle East and Africa Therapeutic Antibody Market Segmentation: By Application

8.7.1 Middle East and Africa Therapeutic Antibody Market, By Application Overview

8.7.2 Middle East and Africa Therapeutic Antibody Market Size, By Oncology, By Value, 2019H-2029F (USD Billion & CAGR)

8.7.3 Middle East and Africa Therapeutic Antibody Market Size, By Autoimmune, By Value, 2019H-2029F (USD Billion & CAGR)

8.7.4 Middle East and Africa Therapeutic Antibody Market Size, By Infectious disease, By Value, 2019H-2029F (USD Billion & CAGR)

8.7.5 Middle East and Africa Therapeutic Antibody Market, By Others, By Value, 2019H-2029F (USD Billion & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on the Global Therapeutic Antibody Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Porter Analysis

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Share of Leading Companies

11.3 Company Profiling

11.3.1 F. Hoffmann-La Roche AG

11.3.2 Bristol-Myers Squibb Co.

11.4.3 AbbVie Inc.

11.3.4 Merck & Co., Inc.

11.3.5 Johnson & Johnson

11.3.6 Novartis

11.3.7 Regeneron Pharmaceuticals

11.3.8 Takeda Pharmaceuticals

11.3.9 Amgen, Inc.

11.3.10 Eli Lilly and Company

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Global Therapeutic Antibody Market (2023 Edition)” which provides a complete analysis of the Global Therapeutic Antibody industry in terms of market segmentation By Product Type (Monoclonal Antibody, Bispecific Antibody, Antibody Drug Conjugates, Others), By Source (Fully Human, Humanized, Others), By Application (Oncology, Autoimmune, Infectious disease, Others), By Region and by Country for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, South Korea, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Therapeutic Antibody Market is expected to generate USD 428.20 billion by the end of 2029, up from USD 211.2 billion in 2022. A favourable growth element for the global Therapeutic Antibody market is propelled by the increasing prevalence of chronic diseases, advancements in biotechnology, and the potential for personalized medicine. During the forecast period, 2024-2029, Global Therapeutic Antibody is expected to expand at a CAGR of 11.2%. Advances in bioprocessing and manufacturing technologies are ongoing. These improvements can lead to increased efficiency, reduced costs, and a more sustainable production of therapeutic antibodies.

According to the World Health Organization (WHO), Noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. The rising incidence of chronic diseases, including cancer, autoimmune disorders, and inflammatory conditions, is a major driver for the therapeutic antibody market. Antibodies can be designed to target specific molecules involved in these diseases, providing targeted and effective treatments.

The COVID-19 pandemic has underscored the importance of therapeutic antibodies in infectious disease management. Antibodies have been developed and authorized for emergency use in the treatment of COVID-19, highlighting their potential in addressing global health challenges. The urgent need for effective treatments during the pandemic has led to expedited development, clinical trials, and regulatory approval processes. This has demonstrated the agility of the industry and regulatory agencies in responding to emerging health crises.

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Advances in precision medicine and the discovery of cancer biomarkers contribute to the development of personalized antibody therapies. Identifying specific molecular targets allows for the design of antibodies tailored to individual patients or specific cancer subtypes.

Researchers continue to engineer antibodies with improved specificity and affinity for their target antigens. This can lead to more effective and precise therapeutic interventions with fewer side effects. Development of novel antibody formats, such as nanobodies, bispecific antibodies, and multispecific antibodies, to expand the therapeutic capabilities and applications.

The utilization of humanized sources in the global therapeutic antibody market offers a range of opportunities, from improving safety and efficacy to expanding target portfolios and enabling advanced engineering approaches. These opportunities contribute to the continued growth and diversification of antibody-based therapies. Advances in antibody engineering have allowed the modification of antibody structures for improved therapeutic properties. Techniques include humanization to reduce immunogenicity, affinity maturation for enhanced binding to target antigens, and isotype switching for optimized effector functions.

Scope of the Report

• The report analyses the Therapeutic Antibody Market by Value (USD Billion).

• The report presents the analysis of the Therapeutic Antibody Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.

• The report analyses the Therapeutic Antibody Market by Product Type (Monoclonal antibody, Bispecific antibody, Antibody-drug conjugates, Others).

• The report analyses the Therapeutic Antibody Market by Source (Fully human, Humanized, Others).

• The report analyses the Therapeutic Antibody Market by Application (Oncology, Autoimmune, Infectious disease, Others).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co., Inc., Johnson & Johnson, Novartis, Regeneron Pharmaceuticals, Takeda Pharmaceuticals, Amgen, Inc., Eli Lilly and Company.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

Azoth Analytics社のバイオテクノロジー分野での最新刊レポート

最新刊レポートはありません。

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

世界の治療用抗体市場（2023年版）：抗体タイプ別（モノクローナル、二重特異性、薬物複合体、その他）、供給源別（完全ヒト、ヒト化、その他）、用途別、地域別、国別の分析：市場インサイトと予測（2019-2029年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

Azoth Analytics社のバイオテクノロジー分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?